Alphamab Oncology (HKG:9966)
Hong Kong · Delayed Price · Currency is HKD 13.70
+0.61 (4.66%)
Sep 30, 2025, 4:08 PM HKT
Alphamab Oncology Market Cap
Alphamab Oncology has a market cap or net worth of 13.31 billion as of September 30, 2025. Its market cap has increased by 505.42% in one year.
Market Cap
13.31B
Enterprise Value
11.80B
Revenue
861.24M
Ranking
n/a
PE Ratio
52.91
Stock Price
13.70
Market Cap Chart
Since December 12, 2019, Alphamab Oncology's market cap has increased from 12.11B to 13.31B, an increase of 9.87%. That is a compound annual growth rate of 1.64%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 29, 2025 | 12.71B | 277.43% |
| Dec 31, 2024 | 3.37B | -47.42% |
| Dec 29, 2023 | 6.41B | -36.87% |
| Dec 30, 2022 | 10.15B | -20.36% |
| Dec 31, 2021 | 12.74B | -16.28% |
| Dec 31, 2020 | 15.22B | 21.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| BeOne Medicines AG | 279.26B |
| Hansoh Pharmaceutical Group Company | 210.92B |
| JD Health International | 206.50B |
| Innovent Biologics | 159.71B |
| WuXi Biologics | 158.73B |
| Sino Biopharmaceutical | 142.12B |
| Akeso | 122.24B |
| Sichuan Kelun-Biotech Biopharmaceutical | 113.38B |